Oncurious NV
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Joint Venture
- Established
- 2015-04-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.oncurious.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Phase 1
Completed
- Conditions
- Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
- Interventions
- Drug: TB-403 50mg/kgDrug: TB-403 100mg/kgDrug: TB-403 175mg/kgDrug: TB-403 20mg/kg
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Oncurious NV
- Target Recruit Count
- 18
- Registration Number
- NCT02748135
News
No news found